文献速递脊柱关节炎

在九个欧洲国家首次启用肿瘤坏死因子抑制剂的银屑病关节炎患者中比较DAPSA、DAPSA28与DAS28-CRP

Comparing DAPSA, DAPSA28, and DAS28-CRP in Patients With Psoriatic Arthritis Initiating a First Tumor Necrosis Factor Inhibitor Across Nine European Countries.
PubMed 文献 · Arthritis Care Res (Hoboken) · 2024-08-19

研究汇总欧洲九国初治银屑病关节炎患者启用首种肿瘤坏死因子抑制剂的前瞻性真实世界数据,在6个月时评估DAPSA、DAPSA28与DAS28-CRP的缓解与应答及基线预测因素。结果显示DAPSA与DAPSA28在缓解、应答及预测因素上高度重叠,作者认为在无法进行66/68关节计数时DAPSA28应优先于DAS28-CRP作为DAPSA的替代。

要点

  • 6个月缓解/应答比例:DAPSA 27%/44%,DAPSA28 28%/44%,DAS28-CRP 59%/80%。
  • 14个候选基线预测因素中11个同时预测DAPSA与DAPSA28缓解,其中8个也预测二者应答。
  • 作者结论:无法获取66/68关节计数时,DAPSA28应优先于DAS28-CRP替代DAPSA。

核心结论

  • 在银屑病关节炎患者中,当无法进行66/68关节计数时,由于DAPSA与DAPSA28在缓解和应答状态及预测因素上高度重叠,DAPSA28应优先于DAS28-CRP作为DAPSA的替代。

研究设计与样本

  • 汇总欧洲九国初治(bionaive)银屑病关节炎患者启用首种肿瘤坏死因子抑制剂的前瞻性真实世界数据。
  • 在6个月时评估缓解(DAPSA≤4、DAPSA28≤4、DAS28-CRP<2.6)、应答(DAPSA与DAPSA28的75%改善)及DAS28-CRP的EULAR良好/中度应答。
  • 采用多重插补数据的logistic回归分析识别基线预测因素。

主要发现

  • 缓解队列3159例、应答队列1866例。
  • 6个月达到缓解/应答的比例分别为DAPSA 27%/44%、DAPSA28 28%/44%、DAS28-CRP 59%/80%。
  • 14个候选基线预测因素中,11个同时预测DAPSA与DAPSA28缓解,其中8个也预测二者应答;这11个因素中分别有8个和5个预测DAS28-CRP缓解和应答。
  • 正向预测因素包括较长病程、男性、较高CRP;负向预测因素包括较大年龄、较高体重指数、患者疲劳、患者总体、医生总体、健康评估问卷评分及压痛和肿胀关节计数。

关键数值与推荐

  • 缓解定义:DAPSA≤4、DAPSA28≤4、DAS28-CRP<2.6。
  • 应答定义:DAPSA与DAPSA28的75%改善;DAS28-CRP采用EULAR良好/中度应答。

临床怎么用

  • 作者认为,在无法获取66/68关节计数时,DAPSA28应优先于DAS28-CRP作为DAPSA的替代用于监测疾病活动度。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Because 66/68 joint counts are not always performed in routine care, we aimed to determine which of the modified 28-joint disease activity index for psoriatic arthritis (DAPSA28) or 28-joint disease activity score with C-reactive protein (DAS28-CRP) should be preferred for monitoring disease activity in psoriatic arthritis (PsA) when the original DAPSA (66/68 joints) is not available. METHODS: Prospectively collected real-world data of European bionaive patients with PsA initiating a first tumor necrosis factor inhibitor were pooled. Remission and response status were evaluated at 6 months by remission (DAPSA ≤ 4, DAPSA28 ≤ 4, and DAS28-CRP < 2.6), response (75% improvement for DAPSA and DAPSA28), and combined EULAR good/moderate responses for DAS28-CRP. Logistic regression analyses on multiple imputed data were used to identify baseline predictors. RESULTS: Remission and response cohorts included 3,159 and 1,866 patients, respectively. The 6-month proportions achieving remission/response were DAPSA (27%/44%), DAPSA28 (28%/44%), and DAS28-CRP (59%/80%). Of 14 possible baseline predictors, 11 predicted both DAPSA and DAPSA28 remission (8 of which also predicted their response, indicated by "*"): longer disease duration*, male sex*, and higher CRP* were positive, whereas older age*, higher body mass index*, patient fatigue*, and global, physician global, health assessment questionnaire score*, and tender and swollen* joint counts were negative predictors. Eight and five of these predicted DAS28-CRP remission and response, respectively. CONCLUSION: In patients with PsA, DAPSA28 should be preferred over DAS28-CRP as a substitute for DAPSA when 66/68 joint counts are not available because of the large overlap in remission and response status and in predictors between DAPSA and DAPSA28.

来源:Arthritis Care Res (Hoboken),查看原文。版权归原作者所有。

引用

  1. Linde L, Georgiadis S, Ørnbjerg LM, et al. Comparing DAPSA, DAPSA28, and DAS28-CRP in Patients With Psoriatic Arthritis Initiating a First Tumor Necrosis Factor Inhibitor Across Nine European Countries. Arthritis Care Res (Hoboken). 2024. PMID: 38926900. doi:10.1002/acr.25396

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。